EUCTR2010-021218-50-GR进行中（未招募）1 期
A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease
AB Science0 个研究点目标入组 396 人开始时间: 2013年1月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 396
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion criteria
- •1. Male or female patient
- •2. Age = 50 years, weighing more than = 49,9 kg and with a Body Mass Index (BMI) >18 at screening
- •3. Patient and/ or caregiver able to understand the patient card and to follow the patient card procedures in case of signs or symptoms of severe neutropenia or severe cutaneous toxicity, during the first 2 months of treatment
- •4. Menopause = 2 years for female patient
- •5. Patient with dementia of Alzheimer's type, according to DSM-IV criteria
- •6. Patient with probable Alzheimer' disease according to NINCDS-ADRDA criteria
- •7. Patient with MMSE = 12 and = 25 at baseline
- •8. Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at baseline, with no changes foreseen in therapy throughout the study
- •9. Patient with adequate organ function at screening and baseline: Absolute Neutrophils Count (ANC) = 2 x 109/L --Hemoglobin = 10 g/dL
- •Platelets (PTL) = 100 x 109/L AST/ALT = 2.5 ULN Bilirubin = 1.5 ULN
- •Albuminemia > 1 x LLN Urea = 1.5 x ULN
- •Creatinine clearance > 60 mL/min (Cockcroft and Gault formula)
- •Proteinuria < 30 mg/dL on dipstick; in case of the proteinuria = 30 mg/dL, 24 hours proteinuria
- •< 1.5g/24 hours
- •10. Patient with a regular and reliable caregiver. The designated caregiver must be sufficiently familiar with the patient (as determined by the investigator) to provide accurate data. The caregiver must have regular contact with the patient (i.e., an average of 10 or more hours per week), must be able to observe for possible adverse events, must be able to oversee patient’s compliance with the study treatment and to report on the patient’s status and must be able to accompany the patient to all visits
- •11. Patient, identified caregiver and, if applicable, patient surrogate able and willing to comply with study visits and procedures per protocol, understand, sign, and date the informed consent form at screening visit prior to any protocol-specific procedures performed
- •12. Male patient must agree to use one method of medically acceptable forms of contraception (his partner must also use one if she is of child-bearing potential) during the study and for 3 months after the last treatment intake.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 196
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •Exclusion criteria
- •1.Patient with any other cause of dementia not due to Alzheimer's disease, based on specific examination including a brain neuro-imagery exam within the last 6 months:
- •Other central nervous condition causing progressive deficits in memory and cognition, e.g. cerebrovascular disease (patient with not more than 4 microbleeds and not more than 2 lacunes at the MRI could be enrolled in the study), Parkinson's disease, Huntington's disease, brain tumor…
- •Systemic conditions known to cause dementia, e.g., hypothyroidism, untreated vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, HIV infection…
- •Substance-induced dementia
- •2.Patient with Alzheimer disease with severe forms of delusions or delirium (patients with light and mild forms of delusions and delirium will be allowed in the study)
- •3.Patient treated with any registered or putative cognitive/memory enhancer or disease modifier other than donepezil, galantamine, rivastigmine or memantine. (Patient taking Ginkgo Biloba can be enrolled providing it has been taken at a stable dose for at least 6 months).
- •4.Patient with evidence of psychosis and/or use of antipsychotic drugs at screening, or history of significant psychiatric disorder
- •5.Patient with active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster), fungal, mycobacterium, protozoan, or other infection
- •6.Patient with history of infection requiring hospitalization within 2 weeks of screening
- •7.Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •Patient with recent cardiac history (within 6 months) of:
- •-Acute coronary syndrome
- •-Acute heart failure (class III or IV of the NYHA classification)
- •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •Patient with cardiac failure class III or IV of the NYHA classification
- •Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •Syncope without known aetiology within 3 months
- •Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •8.Patient with chronic diarrhea
- •9.Patient presenting with oedemas
- •10.Patient with co existing dermatological disease (e.g. eczema, psoriasis) or history of skin allergy
- •11.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •12.Patient with life expectancy < 1 year
- •Previous medications:
- •13.Patient treated with any investigational agent within 4 weeks of screening
研究者
相似试验
进行中（未招募）
1 期
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed preceding studies with remibrutinibEUCTR2022-001034-11-ATovartis Pharma AG1,021
招募中
3 期
An extension study of long-term efficacy and safety of remibrutinib in the treatment of chronic spontaneous urticaria participants who completed studies with remibrutinibCTRI/2024/01/061150ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from mild to moderate Alzheimer's diseasemild to moderate Alzheimer’s diseaseMedDRA version: 20.0Level: PTClassification code 10012271Term: Dementia Alzheimer's typeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-021218-50-BGAB Science594
进行中（未招募）
1 期
Clinical study for the evaluation of the safety and efficacy of masitinib in patients suffering from mild to moderate Alzheimer's diseasemild to moderate Alzheimer’s diseaseMedDRA version: 20.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0 Level: PT Classification code 10012271 Term: Dementia Alzheimer's type System Organ Class: 10029205 - Nervous system disordersEUCTR2010-021218-50-GBAB Science675
进行中（未招募）
1 期
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed preceding studies with remibrutinibChronic Spontaneous UrticariaMedDRA version: 20.0Level: PTClassification code 10072757Term: Chronic spontaneous urticariaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2022-001034-11-SKovartis Pharma AG1,021